novartis_rm_logo_pos_rgb.png
cosentyx logo r.jpeg

Cosentyx (secukinumab) tailored dosing:

Could your adult patients with PsO or PsA with concomitant PsO benefit?

 
Monday 18 July 2022 | 18:30 BST

Spot_Light_Background.png

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited and is intended for UK healthcare professionals only.

UK | July 2022 | 224387

By clicking the below link (www.mhra.gov.uk/yellowcard) you will leave the Novartis-associated website. This link will take you to a website to which our privacy policy does not apply.

You are solely responsible for your interactions with that website.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

Cosentyx (secukinumab) is indicated for: Adult patients with active psoriatic arthritis, alone or in combination with methotrexate, where response to previous disease-modifying anti-rheumatic drugs has been inadequate; Adult patients with active ankylosing spondylitis with an inadequate response to conventional therapy; Adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence, where response to non-steroidal anti-inflammatory drugs has been inadequate; The treatment of moderate to severe plaque psoriasis in adults and adolescents from the age of 6 who are candidates for systemic therapy.

For adult plaque psoriasis, the recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg. For patients with concomitant moderate to severe plaque psoriasis, please refer to adult plaque psoriasis recommendation.